AI assistant
Sending…
EBOS GROUP LIMITED — Director's Dealing 2018
Sep 2, 2018
64813_rns_2018-09-02_e1ce7049-e834-4132-8a95-3ef1468f2ac0.pdf
Director's Dealing
Open in viewerOpens in your device viewer
==> picture [98 x 27] intentionally omitted <==
Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
| To NZX Limited; and | ||
|---|---|---|
| Name of listed issuer: | EBOS GroupLimited | |
| Date this disclosure made: | 3-Sep-18 | |
| Date of last disclosure: | 22-Sep-17 | |
| Director or senior manager giving disclosure | ||
Full name(s): |
Patrick Davies | |
| Name of listed issuer: | EBOS GroupLimited | |
| Name of related body corporate (if applicable): | N/A | |
| Position held in listed issuer: | Former CEO | |
| Summary of acquisition or disposal of relevant interest (excluding specified derivatives) Class ofaffected quotedfinancialproducts: Nature ofthe affectedrelevantinterest(s): For that relevant interest- |
||
| Class ofaffected quotedfinancialproducts: | Ordinaryshares in EBOS GroupLimited | |
| Nature ofthe affectedrelevantinterest(s): | Trustee of the EBOS Staff Share Plan | |
| For that relevant interest- | ||
| Number held in class before acquisition or disposal: | 71,592 ordinaryshares | |
| Number held in class after acquisition or disposal: | Nil | |
| Current registered holder(s): | Mark Brendon Waller & Patrick Donald Davies as trustees of the EBOS Staff Share Plan |
|
| Registered holder(s) once transfers are registered: | Mark Brendon Waller & John Matthew Cullity as trustees of the EBOS Staff Share Plan |
|
| le) | ||
| Type of affected derivative: | N/A | |
| Class of underlyingfinancialproducts: | N/A | |
| Details of affected derivative- | ||
| The notional value of the derivative (if any) or the notional amount of underlying financial products(if any): |
N/A | |
| A statement as to whether the derivative is cash settled orphysicallysettled: | N/A | |
| Maturitydate of the derivative(if any): | N/A | |
| Expirydate of the derivative(if any): | N/A | |
| Theprice specified in the terms of the derivative(if any): | N/A | |
| Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlyingfinancialproducts: |
N/A | |
| _For that derivative,- _ | ||
| Parties to the derivative: | N/A | |
| If the director or senior manager is not a party to the derivative, the nature of the relevant interestinthe derivative: |
N/A | |
| Details of transactions giving rise to acquisition or disposal | ||
| Total numberoftransactions towhich noticerelates: | 1 | |
| 29-Aug-18 | ||
| Ceased as trustee of the EBOS Staff Share Plan |
||
| N/A | ||
| Nil | ||
| 71,592 ordinaryshares |
If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—
| If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details— |
|||
|---|---|---|---|
| Whether relevantinterestswere acquired ordisposed ofduring a closed period: | No | ||
| Whether prior written clearance was provided to allow the acquisition or disposal to proceed duringthe closedperiod: |
N/A | ||
| Date of theprior written clearance(if any): | N/A | ||
| Summary of other relevant interests after acquisition or disposal: Class ofquoted financialproducts: Nature of relevant interest: For that relevant interest,- Number heldinclass: Currentregisteredholder(s): For a derivative relevant interest,- Type ofderivative: Details of derivative,- |
|||
| The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): |
N/A | ||
| A statement as to whether the derivative is cash settled or physically settled: | N/A | ||
| Maturity date of the derivative (if any): | N/A | ||
| Expiry date of the derivative (if any): | N/A | ||
| The price's specified terms (if any): | N/A | ||
| Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlyingfinancialproducts: |
N/A | ||
| For that derivative relevant interest,- | N/A | ||
| Parties to the derivative: | N/A | ||
| If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative: |
N/A |
Certification
| Certification | ||
|---|---|---|
| I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made. |
||
| Signature of director or officer: | ||
| Date of signature: | ||
| or | ||
| Signature of person authorised to sign on behalf of director or officer: | ||
| Date of signature: | 3-Sep-18 | |
| Name and title of authorised person: | Janelle Cain, General Counsel, EBOS Group Limited |
|
More from EBOS GROUP LIMITED
Share Issue/Capital Change
2026
May 18
Share Issue/Capital Change
2026
May 18
Share Issue/Capital Change
2026
May 17
Share Issue/Capital Change
2026
May 17
Share Issue/Capital Change
2026
May 17
Share Issue/Capital Change
2026
May 17
Capital/Financing Update
2026
May 6
Regulatory Filings
2026
May 5
Regulatory Filings
2026
May 5
Regulatory Filings
2026
May 1